Drug Patents
A federal court in California refused to dismiss a False Claims Act suit that claims pharmaceutical companies Allergan and Adamas misled the U.S. Patent Office into issuing “invalid” patents protecting Alzheimer’s drugs Namenda XR and Namzaric, which allegedly allowed the companies to have a monopoly.
Read more